Edition:
India

AnaptysBio Inc (ANAB.OQ)

ANAB.OQ on NASDAQ Stock Exchange Global Select Market

76.64USD
17 Nov 2017
Change (% chg)

$1.78 (+2.38%)
Prev Close
$74.86
Open
$74.54
Day's High
$79.02
Day's Low
$74.54
Volume
128,446
Avg. Vol
115,366
52-wk High
$79.02
52-wk Low
$15.19

Latest Key Developments (Source: Significant Developments)

Anaptysbio qtrly loss per share $0.45‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Anaptysbio Inc ::Anaptysbio announces third quarter 2017 financial results and provides pipeline updates.Qtrly loss per share $0.45‍​.Q3 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.  Full Article

AnaptysBio reports positive ANB019 top-line phase 1 clinical trial results
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Anaptysbio Inc :Anaptysbio reports positive anb019 top-line phase 1 clinical trial results.Top-line data demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties in study​.ANB019 was well-tolerated by all subjects and no dose-limiting toxicities were observed to date in study​.Plans to initiate phase 2 clinical trials of ANB019 in generalized pustular psoriasis, palmo-plantar pustular psoriasis patients in 2018​.  Full Article

Cormorant Asset Management reports 5.02 pct passive stake in Anaptysbio as of Oct. 19 ‍​
Saturday, 21 Oct 2017 

Oct 20 (Reuters) - Cormorant Asset Management LLC: :Cormorant Asset Management, LLC reports 5.02 percent passive stake in Anaptysbio Inc as of October 19 - SEC filing ‍​.  Full Article

AnaptysBio prices public offering of 3 mln shares at $68.50 per share
Friday, 13 Oct 2017 

Oct 12 (Reuters) - AnaptysBio Inc -:AnaptysBio announces pricing of public offering.Says public offering of 3.00 million common shares priced at $68.50per share.  Full Article

Anaptysbio files for offering of 3 million shares
Wednesday, 11 Oct 2017 

Oct 10 (Reuters) - Anaptysbio Inc :Anaptysbio files for offering of 3 million shares for up to $121.1 million – sec filing .  Full Article

AnaptysBio reports positive data from phase 2A clinical trial of ANB020 in atopic dermatitis
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - AnaptysBio Inc : :AnaptysBio reports positive topline proof-of-concept data from phase 2A clinical trial of ANB020 in atopic dermatitis.AnaptysBio Inc - ‍83 percent of patients achieved EASI-50 at day 29 following a single dose of ANB020​.AnaptysBio Inc - ‍ANB020 was generally well tolerated in all patients as of this interim analysis​.AnaptysBio-Continues to advance its ongoing ANB020 phase 2A studies in adults with severe peanut allergy with topline data expected in Q4 of 2017​.Anaptysbio Inc - ‍during first half of 2018, co plans to initiate a phase 2B randomized, double-blinded, placebo-controlled study​.AnaptysBio Inc - no severe adverse events have been reported to date on ‍ANB020 ​.AnaptysBio- also continues to advance ongoing ANB020 phase 2A studies in adults with severe eosinophilic asthma, topline data expected in first half of 2018​.  Full Article

Frazier Healthcare V, L.P reports 18.5 pct stake in Anaptysbio as of Jan. 31, 2017 - SEC filing
Saturday, 11 Feb 2017 

Anaptysbio Inc :Frazier Healthcare V, L.P reports 18.5 percent stake in Anaptysbio Inc as of January 31, 2017 - SEC filing.  Full Article

Anaptysbio announces clearance of U.S., India, U.K. CTA for ANB020
Tuesday, 13 Dec 2016 

AnaptysBio Inc : AnaptysBio announces clearance of U.S. India and U.K. CTA for ANB020 . AnaptysBio - clearance for anb020regulatory support initiation of phase 2a trials for treatment of adult peanut allergy and atopic dermatitis . AnaptysBio Inc - United Kingdom medicines and healthcare products regulatory agency has cleared company's clinical trial authorisation for ANB020 . AnaptysBio- plans to initiate trials in Q1 of 2017, expects to complete trials during second half of 2017 in both U.S. And UK .AnaptysBio Inc - during first half of 2017, seek regulatory clearance to initiate a phase 2a clinical trial for treatment of severe eosinophilic asthma.  Full Article

Anaptysbio initiates multiple ascending dose cohorts in anb020 phase 1 clinical trial
Wednesday, 6 Jul 2016 

Anaptysbio Inc : Anaptysbio initiates multiple ascending dose cohorts in anb020 phase 1 clinical trial .Plans to conduct future clinical development of anb020 in patients with atopic dermatitis, peanut allergy and asthma..  Full Article

BRIEF-Anaptysbio qtrly loss per share $0.45‍​

* Anaptysbio announces third quarter 2017 financial results and provides pipeline updates